权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A study on clarifying the clinical natural course of Hepatitis C Virus carriers

明确丙型肝炎病毒携带者临床自然病程的研究

基本信息

批准号：
17590514
负责人：
TANAKA Junko
金额：
$ 2.05万
依托单位：
HIROSHIMA UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2005
资助国家：
日本
起止时间：
2005 至 2006
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-17590514/
关键词：
HCV carrier health population analysis of etiology natural course population based study HCC

项目摘要

Our aim is to clarify the clinical natural course of HCV carriers without symptoms who were found at the occasion of donation of their blood or at their health check. We evaluated liver disease of 1019 individuals who were found with HCV infection at blood donation, and they were followed for 5-10 years with or without receiving interferon (IFN). This study we called is a "population based study". And the other hand, we check the cumulative rate for HCC from "hospital based case study" in the literatures. These results of this research can lead to basis and valuable data for preventing HCC in Japan.1) At the baseline, chronic hepatitis was detected in 529 (51.9%) HCV carriers and more frequently in men than women (62.6% vs. 42.5%, p < 0.01); cirrhosis was diagnosed in five (0.5%) and hepatocellular carcinoma (HCC) in one.2) Of the carriers who were followed for 5 years or longer, loss of HCV RNA from serum was achieved in 61 (31.0%) of the 197 treated with interferon (IFN) and only one of the 211 (0.5%) without IFN (p < 0.0001).3) HCC developed in 14 carriers including 6 of the 211 (2.8%) without IFN and 8 of the 197 (4.1%) with IFN (6 non-responders included). Follow-ups of the 949 carriers identified age (p < 0.002), male gender (p < 0.01) and cirrhosis at the baseline as factors contributing to the development of HCC.4) Cumulative incidence rates of HCC during 10 years among carriers found with chronic hepatitis increased in parallel with the age at the baseline. That is, cumulative HCC risk during 10 years was estimated at 18.7% (95% CI : 1.9-35.5%) for carriers aged 60 years or older, 8.7% (0-17.5%) for those in the fifties and 7.2% (0-15.5%) for those in the forties when they presented with chronic hepatitis at blood donation.

我们的目的是澄清在献血或健康检查中发现的无症状丙型肝炎病毒携带者的临床自然病程。我们对1019例献血时发现的丙型肝炎病毒感染者的肝病进行了评估，并对他们进行了5-10年的随访。这项研究我们称之为“基于人口的研究”。另一方面，我们对文献中“以医院为基础的病例研究”中的肝癌累积率进行了检验。这些研究结果可以为日本预防肝细胞癌提供依据和有价值的数据。1)基线时，529例(51.9%)丙型肝炎病毒携带者中检出慢性肝炎，男性高于女性(62.6%vs.42.5%，p&lt；0.01)；2)随访5年或5年以上的携带者中，61例(31.0%)血清HCVRNA阴转率为31.0%，而未应用干扰素的携带者仅1例(0.5%)(P&0.0001)。对949名携带者的随访发现，基线年龄(p&lt；0.002)、男性(p&lt；0.01)和肝硬变是导致肝细胞癌发生的因素。也就是说，60岁或以上的携带者在10年内的累积肝癌风险估计为18.7%(95%CI：1.9-35.5%)，50岁或以上的携带者为8.7%(0-17.5%)，而在献血时出现慢性肝炎的40岁的携带者为7.2%(0-15.5%)。